Lisa Fortier, D.V.M., Ph.D., a past president of the International Cartilage Repair Society, has joined the scientific advisory board of TissueGen Inc., based in Dallas, Texas.
Lisa A. Fortier, D.V.M., Ph.D., Joins TissueGen Scientific Advisory Board
1 min read Premium comments
#christopherknowles#lisafortier#tissuegen
As indicated in the February 27, 2017 news release, “Dr. Fortier is a professor of surgery at Cornell University with a particular interest in translational research including the prevention of post-traumatic osteoarthritis. In addition, her internationally renowned research investigates the clinical application of stem cells and biologics such as platelet-rich plasma and bone marrow concentrate for cartilage repair and tendinosis.”
“Dr. Fortier has received the Jacques Lemans Award from the International Cartilage Repair Society, the New Investigator Research Award from the Orthopaedic Research Society, and the Pfizer Research Award for Research Excellence from Cornell University. She is the vice president of the International Veterinary Regenerative Medicine Society, past president of the International Cartilage Repair Society, and director of the Equine Park at Cornell University.”
“We are excited to welcome Dr. Fortier as a member of our scientific advisory board. Her invaluable expertise will guide our development of ELUTE fiber for controlled sustained delivery of sensitive biologics and pharmaceuticals in orthopedic applications,” said Christopher Knowles, TissueGen president.
Dr. Fortier received her D.V.M. from Colorado State University and completed her Ph.D. and surgical residency training at New York’s Cornell University. She is boarded with the American College of Veterinary Surgeons and practices equine orthopedic surgery at Cornell University and at the Cornell Ruffian Equine Specialists.
Asked what she finds most exciting in the realm of cartilage repair, Dr. Fortier told OTW, “The potential to intervene early in the pathology process after cartilage injury and prevent the progression of cartilage damage thereby mitigating the need for repair.”
“With respect to TissueGen, I am currently advising TissueGen regarding pre-clinical evaluation of growth factor-loaded ELUTE fiber in a suture format for orthopedic applications.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.